Vance Wealth Inc. Makes New $46,000 Investment in Chimerix, Inc. (NASDAQ:CMRX)

Vance Wealth Inc. purchased a new position in Chimerix, Inc. (NASDAQ:CMRX) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 47,320 shares of the biopharmaceutical company’s stock, valued at approximately $46,000.

A number of other large investors have also added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in shares of Chimerix during the 3rd quarter valued at about $6,240,000. Bank of New York Mellon Corp boosted its stake in shares of Chimerix by 190.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 387,638 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Chimerix by 167.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 267,044 shares in the last quarter. Finally, Pale Fire Capital SE bought a new stake in shares of Chimerix during the 3rd quarter valued at about $95,000. Institutional investors own 45.42% of the company’s stock.

Chimerix Price Performance

NASDAQ CMRX traded up $0.01 during trading hours on Friday, reaching $0.90. 228,222 shares of the company’s stock traded hands, compared to its average volume of 276,996. The firm has a market cap of $80.28 million, a PE ratio of -0.98 and a beta of 1.15. Chimerix, Inc. has a 52-week low of $0.88 and a 52-week high of $1.57. The firm has a 50-day simple moving average of $1.06 and a 200 day simple moving average of $1.00.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. Sell-side analysts forecast that Chimerix, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CMRX shares. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Chimerix in a research note on Friday, March 1st. StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Monday, March 4th. Finally, Wedbush reissued an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research report on Monday, February 12th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.